Skip to main content
padlock icon - secure page this page is secure

Selective Histone Deacetylase Inhibitors with Anticancer Activity

Buy Article:

$68.00 + tax (Refund Policy)

HDAC inhibitors (HDACIs), which can be used to kill cancer cells through inhibiting histone deacetylase activity or altering the structure of chromatin, have emerged as efficacious agents in the treatment of cancer. With SAHA, FK228, belinostat and panobinostat approved by the FDA, displaying satisfying activity in both haematological and solid tumors of various tissues, efforts to create selective HDACIs have been attracted attention over the past several years. Herein, we mainly review the progress of selective HDAC inhibitors including class-selective and isoform-selective HDAC inhibitors.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Class I; Class II; Class III; HDAC; HDAC1; HDAC6; Selective histone deacetylase inhibitors

Document Type: Research Article

Publication date: February 1, 2016

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more